Non-Active SPMS
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis (NCT06677710) | Indapta Therapeutics, INC. | 2026-06-30 |
Track Non-Active SPMS automatically
Every clearance here is in the API, with alerts when new ones post.